Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. - Test2 - elhamkhani - TriplyDB

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

http://www.wikidata.org/entity/Q33789084

about

The relationships of markers of cholesterol homeostasis with carotid intima-media thickness The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality Ezetimibe therapy: mechanism of action and clinical update Imaging Atherosclerosis.Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials Origin and therapy for hypertriglyceridaemia in type 2 diabetes Lipid-lowering therapy: who can benefit?Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study Quality of diabetes care in primary health centres in north Al-batinah of oman.Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities Niacin or ezetimibe for patients with, or at risk of coronary heart disease Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Safety of simvastatin and goal attainment for low-density lipoprotein cholesterol in sultan qaboos university hospital.Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.A comparative effect of atorvastatin with other statins in patients of hyperlipidemia.Hypolipidemic Effect of a Blue-Green Alga (Nostoc commune) Is Attributed to Its Nonlipid Fraction by Decreasing Intestinal Cholesterol Absorption in C57BL/6J Mice Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.Impact of ezetimibe on atherosclerosis: is the jury still out?Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk Impact of Atorvastatin Combined with Ezetimibe for the Treatment of Carotid Atherosclerosis in Patients with Coronary Heart Disease.Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes.Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary.Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.The impact of ezetimibe on endothelial function and other markers of cardiovascular risk.Ezetimibe/simvastatin.Assessing individual cardiac risk using extra-cardiac arterial imaging.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Pharmacotherapy of dyslipidemias in the adult population.What combination therapy with a statin, if any, would you recommend?Therapies for diabetic dyslipidaemia.Emerging options in the treatment of dyslipidemias: a bright future?

P2860

Q21003910-B32D7A1E-E37F-4A0F-B0F9-FC9CF43448DE Q24609527-2672FE64-D2DC-4B8D-BCC6-F559DA981F40 Q24630302-7AD6800A-886B-41D1-94E7-A2ADEB172197 Q26764836-D035F852-2545-413C-A12E-CD168C338DC2 Q26797486-425FDBF8-DE4D-4C35-88BF-876B890EECF5 Q26824004-C4321098-E770-49EE-82A6-9EC264B867C4 Q26827432-BC75040A-60FD-4386-B4D6-F60FFC89448F Q28546769-0437189B-FB3E-442C-9001-D0723E2E2BE7 Q30425097-4CCE6119-3724-4D6A-A370-5377A547BC17 Q30430614-C5200B05-EB92-4E10-A026-72B184237DD7 Q33776194-AA17ADF0-A949-41F9-9B90-11853A9E7C4D Q33776230-E0BC95CB-9E09-4600-948C-74F3ECB76F2C Q33881733-6E2A8DC9-0BE4-476C-A675-550DB4BA2CF6 Q33886785-E515BBBB-6928-4021-8106-E59FBF7E5BA3 Q33984025-91DDF235-779E-435A-AF4A-E60EEC334027 Q34018909-2B322237-E016-42C3-9855-550F56547C38 Q34300722-57B8CB62-2ABF-47BA-9C98-54FBE2294A5A Q34334828-3246B4CD-5793-437A-918B-91E174F8D00C Q34721194-5D9BD49B-B9A5-4A17-A7DE-23A27D4ABC84 Q34801961-60A9848A-AC3C-43A8-BCC7-3CB890288A0C Q35179226-D72A1EF4-0918-4F91-BA1E-B2B6D8C01F18 Q35323814-7DE43E16-7F7A-49BD-954B-E53AE96A4F71 Q35837416-0B637D95-729F-4653-9964-544D905C8975 Q35890436-9BC2B115-9D24-4DBA-95B3-EACA1EF81138 Q36263573-F165FEBB-DB2B-487A-9DFE-BD7D92DCA353 Q36585817-E6F2E676-DEB6-4766-8C3C-EE5C75AFB77A Q37151389-D2D93214-D545-48F4-B7BE-A09FE873A6A9 Q37202135-B07904C6-30C5-4097-B91E-DD3A08E6A37C Q37314521-0372CF96-D6F3-434B-A055-0DE7F5404BD8 Q37410207-F02A6D74-94D4-45C7-B1F9-1B4BBE408EB1 Q37427267-E9DD2133-6BA6-4D74-86B6-7AA439834507 Q37434889-F411F4C5-8CAA-4DCD-AFC8-59897763F0C4 Q37634194-1D28FADD-524D-43D6-9D90-BE2D403586E5 Q37646768-581477CB-90E7-42C4-BDD6-1EC993A635A5 Q37732244-B5AEDEE9-CD88-464C-A4B7-133542C6FA3F Q37772510-92336EBF-BA33-4EA0-8691-E348CE4DA83A Q37801374-6B789E19-F6B7-436D-928D-5C8593285F25 Q37812296-BA52790D-CB7E-474D-A5B8-FBF996E412F3 Q37825945-4002BEEA-0691-4BF9-A7A7-79DB879B0C16 Q37842462-2198F27C-350B-49E4-BBC8-56DF80CE0A45

P2860

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

http://www.wikidata.org/entity/Q33789084

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Effect of statins alone versus ...... Native Diabetics Study) trial.

@ast

Effect of statins alone versus ...... Native Diabetics Study) trial.

@en

type

label

Effect of statins alone versus ...... Native Diabetics Study) trial.

@ast

Effect of statins alone versus ...... Native Diabetics Study) trial.

@en

prefLabel

Effect of statins alone versus ...... Native Diabetics Study) trial.

@ast

Effect of statins alone versus ...... Native Diabetics Study) trial.

@en

P1433

Q33789084-A533A5BC-1F32-47EE-B5A0-79E4767FCD9E

P1476

Q33789084-9B145825-C19F-410B-BE70-4D949F7F72F1

P2093

Q33789084-1742565E-F7B9-4833-8D69-B556FA78D5C1

Q33789084-20F185B0-381D-4029-8555-552B6211B817

Q33789084-401EFAA2-06CE-4B3E-9C92-9C30686C28EE

Q33789084-4943F96E-9744-4B6A-98E4-B451F401691B

Q33789084-4E6E7B54-4199-4E0B-BC8C-0B7765860C48

Q33789084-5355D09F-EC68-48EC-BEA6-F7C1B39DADC0

Q33789084-5A2C085B-133F-49C9-9D1E-AA879EEBE863

Q33789084-75DD110E-7CE2-4EA1-B10F-E4676DC7682F

Q33789084-C16048BE-0988-4023-ADAF-E12305880EC4

Q33789084-D998FB2D-EB31-4404-BF36-ADCB1E0E7BFF

P2860

Q33789084-0BFA46EA-E723-4F39-862B-377C217CD01F

Q33789084-0F65C1D5-8B5A-4C70-B526-B89AB8F377AA

Q33789084-294E787C-5048-43CD-BFFB-0AB0E5AFE306

Q33789084-33E8328D-57F9-4A23-A44D-D776DAF12151

Q33789084-46041CE7-7C0A-4CD0-AC90-89E186EF59A3

Q33789084-496689A6-B7D0-4304-87C0-1A24DA79C891

Q33789084-9FBACC20-4980-4394-A9E8-EC06FE9BE337

Q33789084-A3C783C6-C587-4022-BEC4-71CDDD4FB506

Q33789084-B9CE6569-2689-42BB-949B-C28B421F2D4A

Q33789084-BB91122E-7E66-473B-8E5E-F4DC90DAB70B

P304

Q33789084-29CFD0D0-5083-4164-9F50-B0336EC5BBA6

P31

Q33789084-D807FD1B-AB75-4F5E-91EA-B7943C486ADC

P356

Q33789084-B66BF7E8-C3C6-4233-B10A-C6625FD20C49

P407

Q33789084-9006BFD7-0587-4951-8682-0EA9CC0F07FD

P433

Q33789084-292D65FC-004E-4E80-83EE-C989961CFCBD

P478

Q33789084-A2A16FF1-B019-4090-964D-66EC9C8C29F7

P50

Q33789084-3859C1EA-2867-45F1-A396-14D0A1C77EA8

P577

Q33789084-819049B1-AD01-4185-BEE4-4C23D83E9F23

P5875

Q33789084-7FCDEF24-66C7-4DD7-AEFA-758178BDFA7E

P698

Q33789084-55148EC4-5F35-492D-A8FF-E957054A50CD

P921

Q33789084-51A7B53C-63D9-45BE-8213-101968261A56

Q33789084-6FEF5805-80BE-452A-A1C6-34FEFB98F032

P932

Q33789084-7B836CEF-AE13-426C-98D3-1A3FB433C9FA

P356

J.JACC.2008.10.031

P1433

Journal of the American College of Cardiology

P1476

Effect of statins alone versus ...... Native Diabetics Study) trial.

@en

P2093

Angela Silverman

http://www.w3.org/2001/XMLSchema#string

Charlton Wilson

http://www.w3.org/2001/XMLSchema#string

James M Galloway

http://www.w3.org/2001/XMLSchema#string

Jason G Umans

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Henderson

http://www.w3.org/2001/XMLSchema#string

Jerome L Fleg

http://www.w3.org/2001/XMLSchema#string

Mario Stylianou

http://www.w3.org/2001/XMLSchema#string

Mary J Roman

http://www.w3.org/2001/XMLSchema#string

Matthew R Weir

http://www.w3.org/2001/XMLSchema#string

Mihriye Mete

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Simvastatin with or without ezetimibe in familial hypercholesterolemia

Effects of torcetrapib in patients at high risk for coronary events

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.

Rationale, design and methods of the CASHMERE study.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.

P304

2198-2205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2008.10.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Barbara V Howard

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23676101

http://www.w3.org/2001/XMLSchema#string

P698

19095139

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

type-2 diabetes

P932

2854549

http://www.w3.org/2001/XMLSchema#string